---
kind: "section"
citation: "21 U.S.C. § 829a"
title: "21"
title_heading: "Food and Drugs"
number: "829a"
heading: "Delivery of a controlled substance by a pharmacy to an administering practitioner"
release: "119-102"
url: "https://uscodex.org/usc/21/829a"
units:
  - "Chapter 13 — Drug Abuse Prevention and Control"
  - "Subchapter I — Control and Enforcement"
  - "Part C — Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances"
---

# §829a. Delivery of a controlled substance by a pharmacy to an administering practitioner

- (a) **In general—** Notwithstanding [section 802(10) of this title](/usc/21/802.md?p=10), a pharmacy may [deliver](/usc/21/802.md?p=8) a [controlled substance](/usc/21/802.md?p=6) to a [practitioner](/usc/21/802.md?p=21) in accordance with a prescription that meets the requirements of this subchapter and the regulations issued by the Attorney General under this subchapter, for the purpose of administering the [controlled substance](/usc/21/802.md?p=6) by the [practitioner](/usc/21/802.md?p=21) if—
  - (1) the [controlled substance](/usc/21/802.md?p=6) is delivered by the pharmacy to the prescribing [practitioner](/usc/21/802.md?p=21) or the [practitioner](/usc/21/802.md?p=21) administering the [controlled substance](/usc/21/802.md?p=6), as applicable, at the location listed on the [practitioner](/usc/21/802.md?p=21)’s certificate of registration issued under this subchapter;
  - (2) the [controlled substance](/usc/21/802.md?p=6) is a [drug](/usc/21/321.md?p=g-1) in schedule III, IV, or V to be administered—
    - (A) by injection or implantation for the purpose of maintenance or [detoxification treatment](/usc/21/802.md?p=30); or
    - (B) subject to a risk evaluation and mitigation [strategy](/usc/21/1701.md?p=12) pursuant to [section 355–1 of this title](/usc/21/355–1.md) that includes elements to assure safe use of the [drug](/usc/21/321.md?p=g-1) described in [subsection (f)(3)(E)](/usc/21/355–1.md?p=f-3-E) of such section, including a requirement for post-administration monitoring by a health care provider;
  - (3) the pharmacy and the [practitioner](/usc/21/802.md?p=21) are [authorized](/usc/21/360eee–1.md?p=a-6) to conduct the activities specified in this section under the law of the [State](/usc/21/802.md?p=26) in which such activities take place;
  - (4) the prescription is not issued to supply any [practitioner](/usc/21/802.md?p=21) with a stock of [controlled substances](/usc/21/802.md?p=6) for the purpose of general dispensing to patients;
  - (5) except as provided in [subsection (b)](#b), the [controlled substance](/usc/21/802.md?p=6) is to be administered only to the patient named on the prescription not later than 45 days after the date of receipt of the [controlled substance](/usc/21/802.md?p=6) by the [practitioner](/usc/21/802.md?p=21); and
  - (6) notwithstanding any exceptions under [section 827 of this title](/usc/21/827.md), the prescribing [practitioner](/usc/21/802.md?p=21), and the [practitioner](/usc/21/802.md?p=21) administering the [controlled substance](/usc/21/802.md?p=6), as applicable, maintain complete and accurate records of all [controlled substances](/usc/21/802.md?p=6) delivered, received, administered, or otherwise disposed of under this section, including the [persons](/usc/21/379j–21.md?p=k-10) to whom [controlled substances](/usc/21/802.md?p=6) were delivered and such other information as may be required by regulations of the Attorney General.
- (b) **Modification of number of days before which controlled substance shall be administered—**
  - (1) **Initial 2-year period—** During the 2-year period beginning on October 24, 2018, the Attorney General, in coordination with the [Secretary](/usc/21/802.md?p=24), may reduce the number of days described in [subsection (a)(5)](#a-5) if the Attorney General determines that such reduction will—
    - (A) reduce the risk of diversion; or
    - (B) protect the public health.
  - (2) **Modifications after submission of report—** After the date on which the report described in section 3204(b) of the SUPPORT for Patients and Communities Act is submitted, the Attorney General, in coordination with the [Secretary](/usc/21/802.md?p=24), may modify the number of days described in [subsection (a)(5)](#a-5).
  - (3) **Minimum number of days—** Any modification under this subsection shall be for a period of not less than 7 days.

## Source credit

(Pub. L. 91–513, title II, § 309A, as added Pub. L. 115–271, title III, § 3204(a), Oct. 24, 2018, 132 Stat. 3945; amended Pub. L. 117–215, title I, § 103(b)(1)(E), Dec. 2, 2022, 136 Stat. 2263; Pub. L. 117–328, div. FF, title I, §§ 1262(b)(2), 1264, Dec. 29, 2022, 136 Stat. 5682, 5685; Pub. L. 119–26, § 4(2)(B)(iii), July 16, 2025, 139 Stat. 416; Pub. L. 119–44, title IV, § 401, Dec. 1, 2025, 139 Stat. 689.)

## Notes

### Editorial Notes

### References in Text

Schedules III, IV, and V, referred to in subsec. (a)(2), are set out in section 812(c) of this title.

Section 3204(b) of the SUPPORT for Patients and Communities Act, referred to in subsec. (b)(2), is section 3204(b) of Pub. L. 115–271, title III, Oct. 24, 2018, 132 Stat. 3946, which is not classified to the Code.

### Amendments

2025—Subsec. (a)(2). Pub. L. 119–44, § 401, added par. (2) and struck out former par. (2) which read as follows: “the controlled substance is a narcotic drug in schedule III, IV, or V to be administered for the purpose of maintenance or detoxification treatment and is to be administered by injection or implantation;”.

Pub. L. 119–26, § 4(2)(B)(iii), amended Pub. L. 117–328, § 1262(b)(2). See 2022 Amendment note below.

2022—Subsec. (a)(2). Pub. L. 117–328, § 1262(b)(2), as amended by Pub. L. 119–26, § 4(2)(B)(iii), substituted “the controlled substance is a narcotic drug in schedule III, IV, or V to be administered for the purpose of maintenance or detoxification treatment and is to be administered by injection or implantation;” for “the controlled substance is to be administered for the purpose of maintenance or detoxification treatment under section 823(g)(2) and—”

“(A) the practitioner who issued the prescription is a qualifying practitioner authorized under, and acting within the scope of that section; and

“(B) the controlled substance is to be administered by injection or implantation;”.

Pub. L. 117–215 substituted “823(h)(2)” for “823(g)(2)” in introductory provisions.

Subsec. (a)(5). Pub. L. 117–328, § 1264, substituted “45 days” for “14 days”.

### Statutory Notes and Related Subsidiaries

### Effective Date of 2025 Amendment

Pub. L. 119–26, § 4, July 16, 2025, 139 Stat. 416, provided that the amendment made by section 4(2)(B)(iii) is effective as if included in the enactment of Pub. L. 117–328.